Introduction
============

Heart failure (HF) is a disease causing high morbidity and mortality regardless of therapies [@B1]. Left ventricle (LV) remodeling plays a critical role in the progression of systolic HF. In previous studies, altered expressions of several serum markers of cardiac extracardiac matrix (ECM) turnover were recognized in patients with HF [@B2]-[@B4]. Furthermore, in some recent studies, the serum markers of cardiac ECM turnover provide prognostic value and clinical implications in HF patients [@B2], [@B4]-[@B6]. Among these cardiac ECM markers, type III amioterminal propeptide of procollagen (PIIINP) is one of the most important ones. Serum PIIINP levels have been widely used to evaluate cardiac function [@B5], monitor exercise compacity and exercise tolerance [@B7], and predict prognosis in HF paitnets [@B5]-[@B7]. Matrix metalloproteinase-2 (MMP-2), which involves in the degradation of type IV collagen, is also a useful outcome predictor in patients with HF [@B4]. Besides, tissue inhibitor of metalloproteinase-1 (TIMP-1), which tightly regulates MMP activities, also has been shown to have prognostic implication in HF patients [@B8].

Inflammation pathway seems to play a significant role in development of HF [@B9]-[@B11]. Up to date, more and more evidence has linked macrophage activation and fibrosis to the pathogenesis of HF [@B10], [@B12], and galectin-3 (Gal-3) is one the most possible mediators [@B13]. Gal-3 is a member of the β-galactoside-binding animal lectin family, and its interaction with several ligands at the ECM, including laminin, synexin, integrins, and collagens, could modulate inflammation and immunity [@B14]. A previous study demonstrated that cardiac macrophages could produce Gal-3 after activation. Besides, the researchers also found the Gal-3- binding sites in cardiac fibroblasts and the ECM [@B15]. Moreover, intrapericardial infusion of recombinant Gal-3 in healthy rats led to LV systolic function impairement and increase of myocardial collagen content [@B15]. Among many mediators of interest, microarray studies have shown that Gal-3 is one of the most prominently mediators expressed in failing hearts [@B15].

Recently, several studies demonstrated the clinical prognostic value of Gal-3 in HF [@B16]-[@B23]. In our previous study in HF patients, we noticed significant relationships between Gal-3 and serum markers of cardiac ECM turnover including PIIINP, MMP-2 and TIMP-1 which also have significant clinical implication in HF outcome implication [@B24]. Therefore, a comparison among Gal-3 and serum markers of cardiac ECM turnover is important.

In this study, we tried to compare the impact of Gal-3 and serum markers of cardiac ECM turnover on prognostic prediction of chronic systolic HF patients. The primary goal is to predict all-cause mortality and the secondary goal is to predict all-cause mortality or time to first episode of HF hospitalization.

Methods
=======

Patients
--------

This is an extension study of our previous study in HF patients [@B24]. A total of 105 (81 males and 24 females) patients with chronic HF secondary to left ventricular systolic dysfunction (left ventricular ejection fraction ((LVEF)) ≤50% determined by echocardiography or Tc99m left ventriculography), who regularly visited the HF clinic in National Taiwan University Hospital, were enrolled in this study. Among then, 102 (97%) participated our previous study which was a cross section design to investigate the relation among Gal-3 and various fibrosis markers [@B24]. All patients received a full clinical history and examination performed by a cardiologist. Baseline demographic data, functional status, cardiovascular risk factors and medication were also recorded. The management of these heart failure patients was according to the guidelines of heart failure management [@B25]. Specialist nurse-led telephone visiting was conducted as our previous report [@B26]. The study was approved by the ethical committee of the National Taiwan University Hospital and all subjects gave informed consent in written form.

Laboratory analysis
-------------------

Venous blood samples were collected after overnight fasting. After centrifugation, the serum was stored at -60 °C. Gal-3 was measured by an enzyme-linked immunosorbent assay (ELISA) kit (Bender Medsystems, Vienna, Austria) on a Victor 2 plate reader (Perkin Elmer, Turku, Finland). The intra-assay variances of Gal-3 were 5.6%, and inter-assay were variances of Gal-3 was 8.6%. Brain natriuretic peptide (BNP) was measured by an ELISA kit (BNP-32, Phoenix pharmaceuticals, Belmont, USA). The intra-assay and inter-assay variation was \<5% and \<14%, respectively. Serum type I amioterminal propeptide of procollagen (PINP) was measured by a rapid equilibrium radioimmunoassay (RIA) kit (No. 67034, Orion Diagnostica, Espoo, Finland). The intra-assay and inter-assay variation s were both \< 7%, and the detection limit was 2 μg/l. Serum PIIINP was determined by a coated-tube RIA method (No. 68570, Orion Diagnostica, Espoo, Finland). The intra- and inter-assay variations of serum PIIINP were both \< 5%, and the detection limit was 0.3μg/l. TIMP-1 was measured by an ELISA kit (DTM100, R & D systems, Minneapolis, USA). The intra- and inter-assay variations of serum TIMP-1 were both \< 5%, and the detection limit was 0.08 ng/ml. Serum MMP-2 was measured by an ELISA kit (DMP200, R & D systems, Minneapolis, USA). The intra- and inter-assay variations of this method were \< 6% and \<8%, respectively; the detection limit was 0.16 ng/ml [@B24].

Statistical analysis
--------------------

Demographic data was presented as mean values ± standard deviations or as percentages. Data of Gal-3, BNP, and serum cardiac ECM markers were presented as median and interquartile ranges due to non-normality which is tested by Kolmogorov-Smirnov test. These non-normal variables were log-transformed for further analysis. Pearson\'s correlation test was used to analyze the association between two variables.

Receiver operating characteristic (ROC) curves were performed and compared to estimate the prognostic capacity of Gal-3 and serum cardiac ECM markers. Furthermore, using the median value as cut-point, Kaplan-Meier survival curve with log-rank test was done to compare in patients with higher and lower levels of serum Gal-3 or cardiac ECM markers. Then, Cox regression analysis was used for survival analysis. A probability value of p \< 0.05 was considered statistically significant and that of 0.05 \< p \< 0.1 was considered as borderline significance. Statistical analyses were performed with SPSS for Windows, version 10.0 (SPSS Inc., Chicago, IL, USA).

Results
=======

Baseline characteristics of HF patients
---------------------------------------

There were 105 (81 males and 24 females) patients participated in this study, and the mean age was 62 ± 15 years and LVEF was 38 ± 11%. Their mean NYHA was 2.l and the patient numbers of NYHA I/II/III/IV were 18/59/28/0, respectively. Other clinical data, including Gal-3, serum cardiac ECM markers, and medication history were shown in Table [1](#T1){ref-type="table"}. During 980±346 days follow-up, 17 patients died and 36 episodes of heart failure admission happened.

Correlations between Gal-3 and serum cardiac ECM markers
--------------------------------------------------------

Log Gal-3 significantly correlated with log PIIINP (r=0.314, p=0.001), log TIMP-1 (r=0.286, p=0.003), log MMP2 (r=0.295, p=0.002), log BNP (0.234 p=0.016).

Prognostic value of Gal-3 and serum cardiac ECM markers for mortality
---------------------------------------------------------------------

In ROC curve analysis for predicting mortality of patients (Figure [1](#F1){ref-type="fig"}), the area under the curve (AUC) of log MMP-2, log TIMP-1, log BNP, log PIIINP, log Gal-3, log PINP, and log MMP-9 were 0.786, 0.699, 0.636, 0.625, 0.607, 0.519, and 0.367 respectively.

Kaplan-Meier analysis of cumulative rates of survival was showed in Figure [2](#F2){ref-type="fig"}. The systolic HF patients presenting Gal-3 concentration lower than the median value, 9.75ng/ml, had non-significantly higher survival rate than those who had higher galectin-3 level (p=0.153). In contrast, patients presenting MMP-2 or TIMP-1 concentration lower than the median value had significantly higher survival rate than those who had higher MMP-2 or TIMP-1 level (p=0.001 for MMP-2 and p=0.028 for TIMP-1).

Mortality of these patients was significantly associated with the log PIIINP (β= 15.380; P=0.042), log TIMP-1(β= 44.530; P=0.003), log MMP-2 (β= 554.336; P\<0.001), log BNP (β= 28.273; P=0.034), age (β= 1.075; P\<0.001), and NYHA functional status (β= 6.301; P\<0.001). Log Gal-3 (β= 7.484; P=0.066) and log MMP-9 (β= 0.212; P=0.073) only had borderline significance to the mortality (Table [2](#T2){ref-type="table"}).

In the models adjusting clinical parameters (Table [3](#T3){ref-type="table"}), log MMP-2 remained significance in five models. Log TIMP-1 remained significance in first three models, and became borderline significance in model 4 and 5. In contrast, log Gal-3 was not significantly associated with mortality in all five models. Log BNP was associated with mortality in model 1 and 5. Log MMP-9 was associated with mortality in model 5.

Prognostic value of Gal-3 and serum cardiac ECM markers for mortality or first HF admission
-------------------------------------------------------------------------------------------

Kaplan-Meier analysis of cumulative rates of HF admission-free survival was shown in Figure [3](#F3){ref-type="fig"}. The systolic HF patients presenting Gal-3 concentration lower than the median value had non-significantly higher survival rate than those who had higher Gal-3 level (p=0.166). Patients presenting MMP-2 concentration lower than the median value had significantly higher survival rate than those who had higher MMP-2 level (p\<0.001). Patients presenting TIMP-1 concentration lower than the median value had borderline significantly higher survival rate than those who had higher TIMP-1 level (p=0.085).

As shown in Table [4](#T4){ref-type="table"}, mortality or first HF admission of these patients was significantly associated with the log TIMP-1(β= 16.496; P=0.006), log MMP-2 (β= 221.864; P\<0.001), log BNP (β= 5.999; P=0.034), age (β= 1.063; P\<0.001), and NYHA functional status (β= 4.370; P\<0.001). Log Gal-3 (β= 4.486; P=0.095) and log MMP-9 (β= 0.313; P=0.079) only showed borderline significance.

In the models adjusting clinical parameters (Table [5](#T5){ref-type="table"}), log MMP-2 remained significance in five models. Log TIMP-1 remained significance in first three models, and became no significance in model 4 and 5. In contrast, log Gal-3 was not significantly associated with mortality in all five models. Log MMP-9 was associated with mortality or first HF admission in model 5.

Discussion
==========

This study verified the values of these biomarkers in predicting clinical outcomes of HF. The results showed that the level of serum Gal-3 concentration had insignificant correlations to both overall and event-free survival, while serum MMP-2 showed better significance. This implicated that high level of serum Gal-3 could be a risk factor associating with outcomes of systolic HF patients and a likely clinically useful prognostic biomarker, but not as good as serum MMP-2. Furthermore, the predict ability of serum Gal-3 may be secondary to the predict ability of serum MMP-2 due to the high correlation between these factors.

Gal-3 has been thought as a potential biomarker for HF since Sharma et al observed that it is increased in decompensated heart failure in homozygous Ren-2 rats and published the first report in human subjects about increase of Gal-3 in the biopsies from patients with aortic stenosis with depressed ejection fraction [@B15], [@B27]. Van Kimmenade et al conducted the first clinical study and reported the value of Gal-3 in diagnosing acute HF and predicting short-term prognosis [@B21]. Moreover, analyzing the data from DEAL-HF study, Lok et al, further postulated that serum Gal-3 could be a novel prognostic marker in chronic HF patients [@B16].

Since then, more and more studies have investigated the correlations between Gal-3 and HF [@B17], [@B18], [@B28]. However, while many studies showed positive believes in Gal-3 as a novel biomarker, some have suggested modified opinions. For instance, defining HF with preserved ejection fraction, de Boer et al, concluded that Gal-3 could be an independent marker for outcome in HF but, in particularly, useful in HF patients with preserved LVEF [@B19]. In contrast, the predict ability was much lower in patients with HF with reduced LVEF. This result might explain the results of our study that Gal-3 had only borderline significance in predicting HF outcomes when we selected our patients with systolic HF with LVEF ≤ 50%.

Previous animal studies have demonstrated that increasing Gal-3 expressed by macrophages could activate fibroblasts via changes in expressions of cell cycle regulators, like cyclin D1, and induce fibrosis in different tissues, including lungs, kidneys and heart, which implies that Gal-3 might be a pro-fibrotic mediator in fibrosis process [@B16], [@B29], [@B30]. Since cardiac ECM markers, such as MMPs and TIMPs, regulate degrees of cardiac ECM turnover, the associations between Gal-3 and cardiac ECM markers would be significantly close due to their connections to fibrosis [@B31]. This explains the significant correlations between Gal-3 and cardiac ECM markers shown in our results. However, as a pro-fibrotic mediator, Gal-3 might have less association to the fibrosis, comparing with cardiac ECM markers, which directly regulate cardiac ECM integrity; therefore, prognostic strength of Gal-3 to the mortality might not be as strong as that of cardiac ECM markers.

MMP-2, MMP-9 and TIMP-1 have been demonstrated to contribute to ventricular remodeling and myocardial apoptosis in experimental pacing-induced HF model [@B32]. In clinical study, the circulating concentration and activity of MMP-2 and TIMP-1 also have been shown to be significantly correlated with HF development and have prognostic value in HF outcomes [@B3], [@B4], [@B8]. The results of our study further supported this observation. In addition, our study also showed that MMP-2 had higher significance than Gal-3 in predicting clinical outcome in systolic HF patients. However, in our study, MMP-2 had found to have significant correlations with clinical outcome in all models. In contrast, MMP-9 showed no significant relations with clinical outcome in unadjusted and four adjusted models (mole 1-4), which is similar to the results of Vorovich *et al* [@B33]. However, in model 5, MMP-9 was significantly correlated with clinical outcome after adjusting twelve clinical parameters. The prognostic value of MMP-9 for HF patients\' needs further study.

PIIINP is another biomarker of interest in predicting HF outcomes. Several studies have suggested that PIIINP is an independent biomarker in predicting HF progression and associating with risks of worse outcomes [@B6], [@B34], [@B35]. From the CARE-HF trial, Natalia et al compared prognostic strength of Gal-3, PIIINP and MMP-1 [@B23]. They reported that increased Gal-3 and PIIINP in systolic HF patients were associated with death or hospitalization, and MMP-1 ≤3ng/mL was associated with death or LVEF ≤35% at 18 months [@B23]. With less number of patients than CARE-HF trial, we observed Gal-3 and PIIINP only had borderline significant prognostic strengths to the HF outcomes, but MMP-2 and TIMP-1 were significantly better. Although our results support the observation that PIIINP or Gal-3 could be a prognostic biomarker of HF, it might also implicate that prognostic strength of MMP-2 is stronger than that of Gal-3 and PIIINP.

Gal-3 is an inflammatory mediator which induces and activates the progression of fibrosis. Gal-3 is also known to regulate many aspects of inflammatory cell behavior, and contributes to atherosclerotic plaque progression by enhancing monocyte chemoattraction through macrophage activation [@B36]. Gal-3 is also a marker of plague instability. In patients with coronary artery disease, unstable patients had a four-fold higher plasma Gal-3 levels in respect to the stable subjects regarding the left ventricular function [@B37]. In condition of HF, Gal-3 induces and activates the progression of fibrosis and play the role as a bridge connecting from inflammation to fibrosis. Therefore, plasma Gal-3 level may reflect the potential of further fibrosis process or cardiovascular event. In patients with acute coronary syndromes, higher concentration of Gal-3 is associated with risk of developing HF [@B18] and clinical events [@B38]. In Framingham Heart Study, higher concentration of Gal-3 is also associated with increased risk for incident HF and mortality in population without HF and very low prevalence of coronary artery disease [@B39]. In another study, Gal-3 predicts all-cause mortality in the general population [@B40].

In the relation among Gal-3 and fibrosis markers, Gal-3 is weakly but significantly correlated to type I collagen telopeptide (r = 0.27, P \<0.0001), but not MMP-1 (r=-0.06, p=0.42), PIIINP (r=0.02, p-0.72), and PINP (r=0.11, p=0.12) in CARE-HF study [@B23]. In contrast, our finding is not like the data from CARE-HF. The association among Gal-3 and fibrosis markers is not fully studied in current stage. To our knowledge, only two studies reporting the relations (our previous study [@B24] and CARE-HF study). Several reasons may explain this situation. First, the racial difference may play a role. The Gal-3 levels are lower in Chinese than western countries in HF groups [@B23], [@B24]. In patients with acute coronary syndrome, another study done in Taiwan [@B38] also showed the same situation comparing with patients with acute coronary syndrome in TIMI-22 study [@B18]. Second, the different kits of testing biomarkers may cause difference. Third, difference of medication may also interfere the relation. The usage of angiotensin converting enzyme inhibitor/ angiotensin receptor blocker, beta-blocker and spironolactone is higher in CARE-HF than in the present study.

Several limitations were inherited in this study. This study has a relatively small patient number and is an extension study for our previous study. Small patient number may not enough to make the final conclusion and blunt the prognostic prediction ability of other serum markers such as BNP. Thus, a larger scale follow-up study is needed to validate the prognostic value of Gal-3 and other cardiac ECM markers. Next, there seems to have racial difference in Gal-3 levels [@B23], [@B24]. The low median level of Gal-3 could be an explanation of the moderate prognostic value of galectin-3 in this population. Therefore, a future study to verify the prognostic value of Gal-3 and other cardiac ECM markers should be performed in other races. Finally, a longer period of follow-up might be crucial to differentiate and ascertain prognostic value of each biomarker.

In conclusion, Gal-3 is significantly correlated with the serum markers of cardiac ECM turnover. The prognostic strength of MMP-2 to clinical outcome prediction in HF patients is stronger than Gal-3.
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###### 

Clinical data of patients (n=105).

  --------------------------------------------------
  Patient characteristics      Data
  ---------------------------- ---------------------
  Age (years)                  62 ± 15

  Male/Female                  81/24

  LVEF (%)                     38 ± 11

  NYHA Fc\                     2.1± 0.7\
  I/II/III/IV                  18/59/28/0

  Body weight (kg)             68 ± 16

  Body height (cm)             165 ± 9

  Body mass index (Kg/m^2^)    25± 4

  Creatinine (mg/dL)           1.6 ± 1.3

  Triglyceride (mg/dL)         156 ± 120

  Cholesterol (mg/dL)          188 ± 46

  HDL (mg/dL)                  42± 9

  LDL (mg/dL)                  105 ± 40

  WBC (/μl)                    7.1 ± 2.4

  Hemoglobin (g/dL)            13.5 ± 2.1

  Etiology for heart failure   

  Ischemic                     46 (44)

  Non-ischemic                 59 (56)

  Hypertension                 49 (47)

  Diabetes mellitus            29 (28)

  Atrial fibrillation          31 (30)

  Medication                   

  ACE-I                        21 (20)

  ARB                          47 (45)

  β-blocker                    58 (55)

  Loop diuretics               74 (70)

  Digoxin                      56 (53)

  Spironolactone               33 (31)

  BNP, pg/ml                   2019 (1604-2541)

  Gal-3, ng/ml                 9.75 (7.08-12.69)

  PINP, μg/L                   33.8 (24.7-47.6)

  PIIINP, μg/L                 6.07 (4.74-7.19)

  TIMP-1 ng/ml                 135.8 (101.2-177.8)

  MMP-2 ng/ml                  256.5 (221.0-319.0)

  MMP-9 ng/ml                  48.0 (30.4-87.5)
  --------------------------------------------------

Abbreviations: NYHA Fc= New York Heart Association functional classification; ACE-I= angiotensin converting enzyme inhibitor; ARB= angiotensin receptor blocker; BNP= brain natriuretic peptide; Gal-3= Galectin-3; PINP = type I amioterminal propeptide of procollagen; PIIINP = type III amioterminal propeptide of procollagen; TIMP = tissue inhibitor of metalloproteinase; MMP = matrix metalloproteinase.

###### 

Cox regression analysis for prediction of mortality using single variable.

                            β (95% CI)                    P value
  ------------------------- ----------------------------- ---------
  Log Gal-3                 7.484 (0.873, 64.156)         0.066
  Log PINP                  2.473 (0.216, 28.340)         0.467
  Log PIIINP                15.380 (1.108, 213.582)       0.042
  Log TIMP-1                44.530 (4.367, 454.056)       0.003
  Log MMP-2                 554.336 (16.800, 17637.141)   \<0.001
  Log MMP-9                 0.212 (0.039, 1.159)          0.073
  Log BNP                   28.273 (1.282; 623.754)       0.034
  Age                       1.075 (1.034, 1.117)          \<0.001
  Sex, male                 0.973 (0.317, 2.986)          0.973
  Creatinine, mg/dl         1.173 (0.906, 1.520)          0.226
  NYHA Fc                   6.301 (2.483, 15.986)         \<0.001
  LVEF                      0.996 (0.954, 1.039)          0.848
  Usage of ACEI/ARB         1.110 (0.410, 3.002)          0.837
  Usage ofβ-blocker         0.702 (0.271, 1.821)          0.467
  Usage of spironolactone   0.825 (0.291, 2.344)          0.719
  Usage of digoxin          0.980 (0.378, 2.541)          0.967
  Ischemic origin of HF     1.459 (0.563, 3.783)          0.437
  Hypertension              0.826 (0.315, 2.171)          0.699
  Diabetes mellitus         2.381 (0.918, 6.172)          0.074

Abbreviations: ACE-I= angiotensin converting enzyme inhibitor; ARB= angiotensin receptor blocker; BNP= brain natriuretic peptide; Gal-3= Galectin-3; HF=heart failure; LVEF= left ventricular ejection fraction; MMP = matrix metalloproteinase; NYHA Fc= New York Heart Association functional classification; PINP = type I amioterminal propeptide of procollagen; PIIINP = type III amioterminal propeptide of procollagen; TIMP = tissue inhibitor of metalloproteinase.

###### 

Cox regression analysis for prediction of mortality after adjusting clinical parameters.

                    Log Galectin-3   Log PINP   Log PIIINP   Log TIMP-1   Log MMP-2   Log MMP-9   Log BNP
  --------- ------- ---------------- ---------- ------------ ------------ ----------- ----------- ---------
  Model 1   β       5.587            4.892      14.141       96.433       1529.582    0.354       21.466
  p         0.138   0.225            0.059      0.002        0.002        0.196       0.028       
  Model 2   β       5.028            4.799      12.114       89.736       1367.862    0.380       18.599
  p         0.154   0.228            0.092      0.002        0.002        0.227       0.040       
  Model 3   β       5.048            4.790      11.154       109.041      1562.154    0.362       17.300
  p         0.152   0.223            0.102      0.002        0.002        0.205       0.053       
  Model 4   β       2.576            1.072      0.866        31.186       207.160     0.324       8.893
  p         0.381   0.959            0.939      0.052        0.027        0.169       0.102       
  Model 5   β       3.095            3.110      0.965        16.276       1320.064    0.138       35.427
            p       0.374            0.503      0.786        0.096        0.009       0.025       0.020

Model 1 adjusted by age.

Model 2 adjusted by age and sex.

Model 3 adjusted by age, sex, and LVEF.

Model 4 adjusted by age, sex, LVEF, and NYHA Fc.

Model 5 adjusted by age, sex, LVEF, creatinine, NYHA Fc, presence of hypertension, presence of diabetes mellitus, ischemic origin of HF, usage of ACEI or ARB, usage of β-blocker, usage of spironolactone, and usage of digoxin.

Abbreviations: ACE-I= angiotensin converting enzyme inhibitor; ARB= angiotensin receptor blocker; HF=heart failure; MMP = matrix metalloproteinase; NYHA Fc= New York Heart Association functional classification; PINP = type I amioterminal propeptide of procollagen; PIIINP = type III amioterminal propeptide of procollagen; TIMP = tissue inhibitor of metalloproteinase.

###### 

Cox regression analysis for prediction mortality or first HF admission using single variable.

                            β (95% CI)                   P value
  ------------------------- ---------------------------- ---------
  Log Gal-3                 4.486 (0.768; 26.191)        0.095
  Log PINP                  0.707 (0.093; 5.368)         0.737
  Log PIIINP                8.278 (0.957; 71.603)        0.055
  Log TIMP-1                16.496 (2.193; 124.066)      0.006
  Log MMP-2                 221.864 (13.477; 3652.544)   \<0.001
  Log MMP-9                 0.313 (0.086; 1.143)         0.079
  Log BNP                   5.999 (0.460; 78.301)        0.034
  Age                       1.063 (1.031, 1.095)         \<0.001
  Sex, male                 1.287 (0.485, 3.415)         0.612
  Creatinine, mg/dl         1.171 (0.856, 1.603)         0.324
  NYHA Fc                   4.370 (2.189, 8.721)         \<0.001
  LVEF                      1.010 (0.976, 1.045)         0.557
  Usage of ACEI/ARB         0.751 (0.345, 1.626)         0.471
  Usage of β-blocker        0.565 (0.259, 1.231)         0.151
  Usage of spironolactone   0.577 (0.232, 1.436)         0.237
  Usage of digoxin          0.775 (0.359, 1.677)         0.518
  Ischemic origin of HF     1.902 (0.873, 4.142)         0.105
  Hypertension              1.053 (0.487, 2.278)         0.895
  Diabetes mellitus         2.099 (0.963, 4.572)         0.062

Abbreviations: ACE-I= angiotensin converting enzyme inhibitor; ARB= angiotensin receptor blocker; BNP= brain natriuretic peptide; Gal-3= Galectin-3; HF=heart failure; LVEF= left ventricular ejection fraction; MMP = matrix metalloproteinase; NYHA Fc= New York Heart Association functional classification; PINP = type I amioterminal propeptide of procollagen; PIIINP = type III amioterminal propeptide of procollagen; TIMP = tissue inhibitor of metalloproteinase.

###### 

Cox regression analysis for prediction of mortality or first HF admission after adjusting clinical parameters.

                    Log Galectin-3   Log PINP   Log PIIINP   Log TIMP-1   Log MMP-2   Log MMP-9   Log BNP
  --------- ------- ---------------- ---------- ------------ ------------ ----------- ----------- ---------
  Model 1   β       3.639            1.132      5.465        14.906       198.288     0.392       7.082
  p         0.144   0.908            0.140      0.030        0.002        0.114       0.092       
  Model 2   β       3.348            1.091      3.651        13.081       182.747     0.414       5.692
  p         0.145   0.993            0.276      0.037        0.002        0.126       0.131       
  Model 3   β       3.444            1.081      3.875        12.749       179.315     0.419       6.385
  p         0.139   0.940            0.261      0.038        0.002        0.133       0.114       
  Model 4   β       2.279            0.485      0.708        2.711        48.807      0.389       4.333
  p         0.295   0.483            0.802      0.514        0.021        0.102       0.173       
  Model 5   β       4.455            0.359      0.331        1.729        101.504     0.210       5.606
            p       0.118            0.428      0.514        0.723        0.011       0.023       0.143

Model 1 adjusted by age

Model 2 adjusted by age and sex

Model 3 adjusted by age, sex, and LVEF

Model 4 adjusted by age, sex, LVEF, and NYHA Fc

Model 5 adjusted by age, sex, LVEF, creatinine, NYHA Fc, presence of hypertension, presence of diabetes mellitus, ischemic origin of HF, usage of ACEI or ARB, usage of β-blocker, usage of spironolactone, and usage of digoxin

Abbreviations: ACE-I= angiotensin converting enzyme inhibitor; ARB= angiotensin receptor blocker; HF=heart failure; MMP = matrix metalloproteinase; NYHA Fc= New York Heart Association functional classification; PINP = type I amioterminal propeptide of procollagen; PIIINP = type III amioterminal propeptide of procollagen; TIMP = tissue inhibitor of metalloproteinase.

[^1]: Competing Interests: The authors have declared that no competing interest exists.
